课题基金 / 基金详情

A Highly Specific Point-of-Care Rapid Real-time Sensing Device for COVID-19

A Highly Specific Point-of-Care Rapid Real-time Sensing Device for COVID-19
针对 COVID-19 的高度特异性护理点快速实时传感设备
批准号:
10158992
负责人:
Dipanjan Pan
金额:
$7.04万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-15 至 2022-05-31

项目摘要

项目成果

Dipanjan Pan的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 自美国(美国)报告首例COVID-19病例以来,本集团已于二零二零年十二月三十一日(星期四)开始对COVID-19进行评估。2020年1月21日, 已确定影响> 90万例活动病例,死亡> 5万例。目前,COVID-19正在被诊断为 主要通过三种技术,即逆转录聚合酶链反应(RT-PCR)、基因工程(PCR)和基因工程(PCR), 测序和胸部计算机断层扫描(CT)。然而,样本收集的局限性和 运输,以及工具包的性能与先进的仪器技术不足,往往 不能在最初出现时报告COVID-19,导致这种传染病传播到更广泛的地区, 社区此外,研究人员还发现了至少三种中心变异,它们可以通过氨基酸来区分。 在160个不同的完整的人类SARS-CoV-2基因组序列中,这限制了普遍性 目前可用的商业COVID-19试剂盒的适用性。在这个建议中,我们提出了一种新的方法, 用于使用电化学定量生物传感器筛查活动性COVID-19病例。这种独特的方法 用于选择性传感SARS-CoV-2消除了由于基因组 这种病毒的变体是目前COVID-19传感试剂盒最令人担忧的限制。我们 预期我们的传感器可以检测特定的靶核酸序列,而没有信号串扰, 检测极限为约50 fg/ml,响应时间为约2-3分钟。
英文摘要
ABSTRACT Since the first case of COVID-19 was reported in the United States (U.S.) on January 21st, 2020, it has already been ascertained to affect >900K active cases with >50K deaths. Currently, COVID-19 is being diagnosed primarily by three techniques, i.e. reverse-transcription polymerase chain reaction (RT-PCR), gene sequencing and chest computed tomography (CT). However, limitations of sample collection and transportation, as well as kit performance with inadequate access to advanced instrumental techniques, often cannot report COVID-19 at its initial presentation leading to the spread of this infectious disease to a wider community. Moreover, researchers found at least three central variants, distinguishable by amino acid changes, among 160 different complete human SARS-CoV-2 genome sequences. This limits the universal applicability of the currently available commercial COVID-19 kits. In this proposal we present a novel approach for screening of active COVID-19 cases with an electrochemical quantitative biosensor. This unique approach for selective sensing of SARS-CoV-2 eliminates the possibility of misinterpretation arisen due to the genomic variants of this virus which is the most concerning limitation of the current COVID-19 sensing kits. We anticipate that our sensor can detect the specific target nucleic acid sequences without signal cross talk with a detection limit to be around 50 fg/ml with time of response to be around 2-3 mins.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s42003-021-02372-y
发表时间: 2021-07-15
期刊: Communications biology
影响因子: 5.9
作者: [Ostadhossein F, Moitra P, Altun E, Dutta D, Sar D, Tripathi I, Hsiao SH, Kravchuk V, Nie S, Pan D]
通讯作者: Pan D
DOI: 10.1016/j.bios.2021.113900
发表时间: 2022-03-15
期刊: Biosensors & bioelectronics
影响因子: 12.6
作者: [Dighe K, Moitra P, Alafeef M, Gunaseelan N, Pan D]
通讯作者: Pan D
DOI: 10.1002/adhm.202000136
发表时间: 2020-07
期刊: Advanced healthcare materials
影响因子: 10
作者: []
通讯作者:
DOI: 10.1002/advs.202202414
发表时间: 2022-08
期刊: ADVANCED SCIENCE
影响因子: 15.1
作者: [Sar, Dinabandhu, Ostadhossein, Fatemeh, Moitra, Parikshit, Alafeef, Maha, Pan, Dipanjan]
通讯作者: Pan, Dipanjan
A Sensing Platform for Rapid at Home-Test of COVID-19
海外基金